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1. Introduction
   Candida albicans (C. albicans) is commensal yeast 
normally present in small numbers as a skin, oral, gut or 
vaginal flora and is found in 15%-60% of the population. C. 
albicans is traditionally regarded as a low grade pathogen. 
A common form of candidiasis that is restricted to the 
mucosal membranes in the mouth or vagina known as 
thrush, which is usually easily treated[1]. Systemic candidal 
infections have emerged as important causes of morbidity 
and mortality in immunocompromised patients[2]. The 
emergence of fungal urinary tract infections (UTIs) poses an 
interesting diagnostic and therapeutic challenge. During the 
past decade, there has been a worldwide trend in increasing 
occurrences of fungal UTIs. C. albicans was reported as 
the most common cause of fungal UTIs (candiduria)[3]. 
Candiduria may be resolved spontaneously, but may also 
result in serious complications if treated inadequately, 
and recurrent or persistent infections are frequent. Many 
risk factors for candiduria found including urinary system 
intervention, catheter use and immunosuppression history. 
There are other risk factors for candiduria including older 
age, sex, antibiotic exposure and diabetes[4].
   Candiduria has raised alarms with the global infectious 
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diseases community because of the limited therapeutic 
options. The limited success over the past decade of prevention 
and control candiduria highlights the difficulty of limiting the 
problem once it has already been established[5]. In contrast to 
antibacterial agents, antifungal agents have less of a clinical 
benefit. This is due to the higher level of toxicity to human 
cells because both fungi and the host cells are eukaryotic 
and share similar cellular structures. In recurrent candiduria, 
long-term antifungals are administered to the patients and this 
is generally unfavourable from the points of medical cost and 
the potential development of fungal resistance[6].
   Current pharmacologic treatment options for symptomatic 
candiduria include amphotericin B, flucytosine, or azole. 
Due to its ease of administration and pharmacokinetic 
profile, fluconazole has emerged as the most commonly used 
drug to treat candiduria. In addition, fluconazole’s adverse 
effect profile may be more tolerable than the complications 
associated with other antifungal agents. However, the failure 
of fluconazole treatments may be associated with either some 
Candida species innate resistance or due to an acquired 
resistance to the drug. The emergence of fluconazole 
resistance in C. albicans was observed after reports showed 
that the long-term use of fluconazole for prophylaxis lead to 
the emergence of resistance[7].
   Therefore, promoting the application of natural plant-
derived antimicrobials as a possible approach to prevent 
recurrent candiduria is very desirable and the potential 
effect of natural options for long-term prevention of 
infections should be explored. Hence, in this study we 
examined the in vitro antimicrobial activities of Hibiscus 
sabdariffa (H. sabdariffa) extract against fluconazole resistant 
C. albicans isolated from recurrent candiduria.  H. sabdariffa 
is a common herbal drink consumed both hot and cold by 
people around the world and used in traditional medicine in 
the treatment of hypertension. The infusion is made from the 
calyces of the H. sabdariffa[8]. Relatively few studies have 
been carried out to evaluate the antimicrobial activities of 
this plant against common human pathogens[9,10]. However, 
no study has been reported concerning the effect of the 
plant in biofilm forming uropathogenic C. albicans and the 
combination effect of H. sabdariffa with other antifungal 
drugs. The aim of this study was to assess the antifungal 
activity of H. sabdariffa extract against C. albicans from 
recurrent candiduria in order to better understand their 
therapeutic properties.
2. Materials and methods
2.1. Preparation of plant extracts
   Air dried Hibiscus calyces were purchased from the 
local market. The identity of the plant was confirmed by 
comparing collected voucher specimen with those of a 
known identity located in the Herbarium of the College 
of Science, Taibah University. A voucher specimen was 
deposited at the Herbarium under the reference number 
1433/14. The extracts were prepared according to a 
previously described protocol[11]. Using 1 L of 80% aqueous 
methanol (BDH, UK), the phenolics were extracted from 100 
g of the grinded calyces. The mixture was then sonicated 
for 20 min and then filtered through Whatman No. 2 filter 
paper. The solvents were then evaporated using a rotary 
evaporator at 40 °C under reduced pressure and the extracts 
were stored in tightly, sealed glass vials and considered to 
be H. sabdariffa extract, and was used for the antibacterial 
assays. Dried plant extracts were then dissolved in 
methanol to give a stock solution of 500 mg/mL and then 
filter sterilized before use.
2.2. Fungal strains and growth conditions
   In this particular study, six strains of fluconazole resistant 
C. albicans, CA1, CA2, CA3, CA4, CA5 and CA6 were used. 
All were obtained from patients with recurrent candiduria 
which had been isolated from Ohad Hospital, Almadinah, 
Saudi Arabia. Fungal identities were confirmed using 
standard microbiologic procedures and the use of API ID 32C 
strips (Biomerieux, France).
2.3. Determination of antimicrobial activity
   The fluconazole and H. sabdariffa extracts minimum 
inhibitory concentrations (MICs) and time-kill curves 
were determined according to the approved CLSI standard 
reference method for broth dilution and antifungal 
susceptibility testing of yeasts M27-A3[12]. MIC plates were 
incubated at 35 °C for 48 h. MICs were defined as the lowest 
concentration of the drug eliminating cell growth using 
MIC-0. MIC-0 was defined as the lowest drug combination 
resulting in optically clear wells. 
2.4. Effect on C. albicans biofilm formation 
   The ability to form a Candida biofilm was tested on 96-
well tissue culture plates and biofilm was quantified by 
measuring the optical density after dyeing it with 0.1% 
crystal violet in accordance to a previously described 
protocol[13]. This method measures the cells adhering to 
the bottom of microtiter plate wells after repetitive cycles 
of washing. Briefly, strains from an overnight culture were 
inoculated with the tested organism in the presence and 
absence of sub-MIC concentrations of the extract at 37 
°C without agitation for 48 h in yeast nitrogen base broth 
+0.5% glucose. The attached cells were washed, fixed and 
stained with crystal violet and air dried. About 0.15 mL of 
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95% ethanol was added in each well and the plates were 
incubated for 10 min. Biofilm formation was quantified by 
measuring the absorbance at 550 nm. Each strain and each 
concentration were assayed in three wells on each plate, 
and all experiments were replicated at least three times. 
2.5. Statistical analysis
   Data was analysed in SPSS statistical software. P<0.05 was 
considered to be statistically significant when compared 
with control.
 
3. Results
3.1. Antifungal activities
   Various levels MIC of H. sabdariffa extract were observed 
against all the isolates. MICs values ranged from 0.5 to 2.0 
mg/mL. All the isolates showed resistance to fluconazole 
with MICs values of >16 µg/mL (P<0.05). The results are 
summarized in Table 1.
Table 1    
Antifungal activities of H. sabdariffa extract and fluconazole against 
C. albicans.
Strain Antifungal agents (µg/mL) Minimum inhibitory concentration
CA1 Fluconazole  64.0
H. sabdariffa extract    2.0
CA2 Fluconazole  32.0
H. sabdariffa extract    1.0
CA3 Fluconazole  32.0
H. sabdariffa extract    2.0
CA4 Fluconazole 128.0
H. sabdariffa extract     2.0
CA5 Fluconazole   64.0
H. sabdariffa extract     0.5
CA6 Fluconazole   64.0
H. sabdariffa extract     1.0
CA: C. albicans
3.2. Mode of action
   Time-kill curves were performed for the isolates using 
different concentrations of the H. sabdariffa extract ranging 
from 0.5-2伊 the MIC value. The results obtained for the 
time-kill curves are summarized in Figure 1. For the six 
strains, the effects were fungistatic (P<0.05). Fungistatic 
activity has been defined as <3 log reduction in CFU/mL 
using time-kill[14]. The present study allows us to establish 
that H. sabdariffa has a fungistatic effect against the C. 
albicans isolates. 
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Figure 1. Time-kill experiments evaluating the activity of H. sabdariffa 
extract against C. albicans isolates. 
Fungistatic activity was defined as a reduction in the numbers of viable 
bacteria of <3 log10 CFU/mL at any of the incubation times tested. P<0.05, 
between growth control and different concentrations of the extracts; 伊: 
Minimum inhibitory concentration of the extract; CA: C. albicans.
3.3. Inhibition of biofilm formation by H. sabdariffa
   There is no previous data that suggests H. sabdariffa may 
inhibit biofilm formation against candiduria isolates. Thus, 
the current study was initiated to evaluate H. sabdariffa 
extracts on those pathogens that are clinically relevant. The 
results showed that the H. sabdariffa extract inhibited biofilm 
production on all of the isolates. The biofilm inhibition varies 
between the different isolates and ranged from 33%-55% 
(P<0.05). The results obtained for the biofilm formation assays 
are summarized in Figure 2. 
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Figure 2. Inhibition of biofilm formation in microtiter plates of C. albicans 
isolates by H. sabdariffa extract. 
All strains showed reduced biofilm formation in the presence of different 
concentrations of H. sabdariffa extract. Biofilm formation was determined by crystal 
violet staining. Values are means of three independent experiments. P<0.05, 
between growth control and different concentrations of the extracts. X: Minimum 
inhibitory concentration of the extract, OD: Optical density, CA: C. albicans.
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4. Discussion
   Few studies have been carried out to evaluate the 
antimicrobial activities of H. sabdariffa extract against 
common bacterial pathogens. Extracts of the plant 
significantly enhanced the inhibitory effects of antibacterial 
agents against different bacterial species[15]. However, 
there has been only one study reported the effect of the 
plant extract against fungal pathogens. H. sabdariffa 
was found to be effective at all levels in inhibiting C. 
albicans (non candiduria isolates) but no other Candida 
species[9]. Previous studies have shown this effect in terms 
of inhibition zones or agar dilution methods. In our study, 
we chose the most appropriate and reliable method for 
antimicrobial susceptibility testing (i.e., the MIC using 
microdilution method). The advantage of this technique was 
that it generated a quantitative result in which with further 
analysis provided a clearer interpretation of the results in 
terms of time-kill. The present study allows us to establish, 
for the first time, the effect of H. sabdariffa extract against 
C. albicans isolated from recurrent UTIs. 
   The high potency of H. sabdariffa against these strains 
gives scientific basis for its use in folk medicine for treating 
and preventing of UTI. The mechanism of the action is 
not fully understood but it has been suggested that H. 
sabdariffa products contain phenolic compounds including 
flavonoids and cyanidin[16,17]. Phenolic compounds have 
been reported to exhibit antimicrobial activities[11,18,19,]. The 
antimicrobial effect of the phenolic compounds may be due 
to iron deprivation or hydrogen bonding with vital proteins 
such as microbial enzymes[20].
   Nearly all Candida species strain possess different ranges 
of virulence factors, including the use of several adherence 
mechanisms to colonize uroepithelium of both the upper 
and lower urinary tract. Biofilm forming uropathogens are 
often associated with long term persistence and display a 
dramatically increased resistance to antimicrobial agents. 
Agents interfering with biofilm formation represent a novel 
approach to control C. albicans infections. By affecting 
C. albicans virulence properties, this may minimize the 
appearance of resistant strains[21,22]. 
   H. sabdariffa contains a unique polymeric compound 
known as proanthocyanidin. Research shows that 
proanthocyanidin from cranberry extracts inhibit the biofilm 
formation of C. albicans isolated from oral infection[13]. 
The present study suggests that proanthocyanidin from 
H. sabdariffa has the same anti-biofilm inhibition effect 
against C. albicans strains isolated from UTIs.
   The use of plant extracts and phytochemicals with 
known antimicrobial properties is becoming a very 
common practice worldwide and is of great significance 
in therapeutic use. The wide extensive use of antifungal 
agents leads to the selection of clinical isolates that show 
multidrug resistance. On the other hand, few synthetic 
antifungals agents are being developed. The identification 
of plant extracts with antimicrobial properties would be of 
an immense practical use as a safe and effective means of 
controlling clinical infections[23,24].
   In conclusion, the current study shows that H. sabdariffa 
extract significantly inhibits the C. albicans growth and 
prevents the formation of in vitro biofilm. The antifungal 
activities of the extract that were observed provide basic 
evidence for the potential effects of this plant for preventing 
recurrent candiduria caused by C. albicans. It also 
emphasizes a significant approach of the plants extract as 
an antimicrobial agent. Although a preventive effect of H. 
sabdariffa has been shown in vitro, further studies with 
a more robust methodology would be needed in order to 
determine the in vivo clinical efficiency of the extract to 
prevent recurrent UTIs.
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Comments 
Background
   H. sabdariffa, commonly known as karkade, grows and 
is cultivated in different parts of the world such as Africa 
and Asia. The calyces parts of plant is used in traditional 
medicine in the treatment of hypertension. Many research 
studies have been carried out to validate its traditional 
uses.
  
Research frontiers
   Current article aimed to evaluate and compare the 
antifungal potential and activity of the methanolic extract 
against C. albicans isolated from candiduria. The authors 
also examined the biofilm inhibition activity of the extract. 
This paper describes for the first time the extract effect 
against fungal isolates from candiduria.
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Related reports
   Relatively, few studies have been carried out to evaluate 
the antimicrobial activities of this plant against common 
human pathogens (Darwish et al., 2010). This study focuses 
on the antifungal effect of H. sabdariffa extract against C. 
albicans isolated from recurrent UTIs.
Innovations and breakthroughs
   This study has shown that H. sabdariffa extract can be 
further developed for use in the treatment of infectious 
diseases.
  
Applications
   This report finds wide applications in medicine. H. 
sabdariffa extract may be used as a local source of 
antifungal agents to treat and prevent UTIs.   
Peer review
   Generally the presentation of the paper is good. 
Methodology is appropriate and the results are presented 
properly. Based on the results, the authors reported a new 
application of this valuable medicinal plant. The results of 
biofilm inhibition indicate that this plant can be used to 
prevent recurrent UTIs.  
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